Mandate

Vinge advises Industrifonden and SEB in connection with Clavister investment

April 16, 2012

Vinge has advised Industrifonden and SEB Venture Capital in connection with their approximately SEK 40 million investment in the security company Clavister AB. The company, which has its registered office in Örnsköldsvik, offers advanced security products focusing on the telecoms industry, cloud computing environments and large corporate customers. The capital will be used for the company’s future international expansion.

SEB Venture Capital was founded in 1995 and is part of the SEB group. With a capital base of SEK 2 500 million, the company has thus far made 36 investments in technology and healthcare enterprises and performed 36 exits. Read more about SEB Venture Capital by visiting www.seb.se/venturecapital

Industrifonden has assets worth SEK 3.8 billion and investments in 89 companies within the technology, cleantech, life science and industrial sectors. This is Industrfonden’s seventh new investment for the financial year comprising 1 July 2011 to 30 June 2012. Read more about Industrifonden by visiting www.industrifonden.se

Vinge’e team consisted of partner Johan Larsson together with associates Philip Watson and Martin Hall.     

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026